Clinical Guides
Cervical Cancer
A clinically focused guide to recognising, confirming, staging and coordinating cervical cancer care in India, with prevention, oncological-emergency safety, fertility considerations and explicit limits on transferring foreign treatment pathways.
MedNext Academy | 14 min read
Cervical Cancer
A clinically focused guide to recognising, confirming, staging and coordinating cervical cancer care in India, with prevention, oncological-emergency safety, fertility considerations and explicit limits on transferring foreign treatment pathways.
Summary
Cervical cancer is an invasive malignancy arising from the cervix, most often after persistent infection with an oncogenic human papillomavirus type and a prolonged phase of precancerous epithelial change. Squamous-cell carcinoma is the commonest histology; adenocarcinoma and less common variants require pathology-led classification. Screening identifies HPV infection or precursor lesions in people without symptoms. It is not the correct endpoint for someone with postcoital bleeding, persistent abnormal discharge, an abnormal-looking cervix or other features of invasive disease: that person needs diagnostic examination and tissue confirmation.
A safe pathway separates prevention, diagnosis and treatment. Prevention includes HPV vaccination, tobacco avoidance, sexual-health care and participation in a quality-assured screening programme. Suspected cancer requires speculum examination when appropriate, urgent specialist referral, biopsy, histological reporting and clinical or imaging assessment of local, nodal and distant extent. Treatment is selected by a gynaecological-oncology multidisciplinary team according to FIGO stage, tumour size, nodal status, histology, fertility goals, renal and general health, and local surgical and radiotherapy expertise. It may involve fertility-sparing surgery, hysterectomy, chemoradiation with brachytherapy, systemic therapy, symptom-directed radiation, or palliative care.
Uncontrolled vaginal bleeding, sepsis, obstructive renal failure, venous thromboembolism and treatment toxicity can become emergencies. No guide can choose a regimen for an individual. The WHO screening recommendations, the United States NCI treatment summary and older Indian programme framework are used for bounded principles, not presented as one current Indian national oncology protocol. This draft remains reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Cervical cancer remains a major preventable cause of illness and death, with a disproportionate burden in countries where vaccination, screening, diagnosis and treatment are difficult to access. WHO's July 2026 fact sheet describes cervical cancer as the fourth most common cancer in women globally and attributes almost all cases to persistent infection with oncogenic HPV. Those global statements do not provide an individual prognosis and should not be converted into a single Indian incidence rate without naming the dataset and estimation year.
The current IARC India country sheet reports modelled national estimates derived from subnational registry data. It places cervix uteri among India's leading cancer sites, but the figures are estimates rather than a complete count of every diagnosis or death. Regional variation can be substantial because age structure, HPV prevalence, tobacco use, socioeconomic conditions, screening coverage, diagnostic access and registry completeness differ. Incidence and mortality are also different measures: a fall in incidence may lag behind prevention, while mortality additionally reflects stage at presentation and access to timely treatment.
The clinical burden includes years of life lost, anaemia and pain from advanced disease, renal and fistula complications, infertility or premature menopause after treatment, sexual and psychological effects, and the financial cost of repeated travel to specialist centres. Screening programmes must measure not only tests performed but also completed triage, treatment of precancer and follow-up. For a clinician, the practical epidemiological message is that cervical cancer is common enough to investigate warning symptoms promptly, yet preventable enough that vaccination and quality-assured screening deserve sustained attention.
Risk Factors
Persistent high-risk HPV infection is the necessary causal pathway for almost all cervical cancers, but most HPV infections clear and do not progress. Risk reflects persistence and failure to detect or treat precursor disease, not a person's character. Immunosuppression, particularly HIV, increases persistence, progression and recurrence risk. Tobacco exposure is associated with squamous carcinogenesis. Earlier sexual exposure and a higher number of partners are population-level proxies for HPV exposure and should never be used to stigmatise or interrogate a patient. A current partner may carry an infection acquired years earlier; HPV detection cannot establish when or from whom transmission occurred.
Limited access to HPV vaccination and screening, missed follow-up after an abnormal result, and inability to reach colposcopy or treatment are health-system risk factors. Previous cervical intraepithelial neoplasia, persistent oncogenic HPV, prior treatment of high-grade disease, in-utero diethylstilbestrol exposure, solid-organ transplantation or other immunosuppressive therapy require programme-specific surveillance. HIV status may alter screening and treatment recommendations, so coordinate with current national HIV and cervical-screening services. Multiparity and long-term hormonal contraceptive exposure appear in epidemiological literature, but associations require contextual interpretation and do not justify stopping effective contraception without counselling.
An overdue screen is not proof of cancer, and a recent negative screen does not make symptoms benign. HPV vaccination substantially reduces risk from covered types but does not treat established infection or eliminate all oncogenic types. Condoms reduce, but do not remove, HPV transmission. Risk reduction therefore combines vaccination, screening, tobacco cessation, HIV care and reliable diagnostic follow-through. Clinicians should document prior results and treatments precisely rather than using vague labels such as an abnormal Pap many years ago.
Diagnosis
History
Ask about postcoital, intermenstrual, postmenopausal or unexplained persistent vaginal bleeding; watery, blood-stained or offensive discharge; pelvic or back pain; dyspareunia; urinary or bowel symptoms; leg swelling; weight loss and functional decline. Establish pregnancy possibility, menstrual and menopausal status, prior HPV or cytology results, colposcopy and treatment, HPV vaccination, HIV or immunosuppression, tobacco exposure, comorbidity and medicines. Quantify bleeding and symptoms of anaemia. Ask sensitively about fertility priorities and support, without making assumptions from age, parity or relationship status.
Examination
Assess haemodynamic stability, pallor, fever, hydration, performance status, abdomen, lymph nodes and leg asymmetry. With consent, privacy, a chaperone and an appropriately skilled examiner, inspect vulva and vagina and perform a gentle speculum examination. A friable, ulcerative, exophytic or irregular cervix, contact bleeding or a suspicious vaginal lesion requires urgent specialist evaluation. Bimanual and rectovaginal assessment for tumour size, parametrial or pelvic-wall involvement belongs with experienced gynaecological oncology care and must not delay referral. Avoid forceful examination during heavy bleeding.
Investigations
Invasive cancer is confirmed histologically, usually by directed cervical biopsy; a cytology or HPV result alone does not establish invasion. Obtain blood count, renal and liver function and other tests according to bleeding, obstruction, comorbidity and planned treatment. Pelvic MRI is valuable for local extent where available; CT or PET-CT may assess nodes and distant disease according to stage and resources. Examination under anaesthesia, cystoscopy or proctoscopy is selective. Preserve the original pathology material for review and relevant biomarker testing in advanced disease. Pregnancy requires specialist modification of imaging and management.
Differential Diagnosis
Abnormal bleeding is common, but its source must be established. Cervical ectropion, a benign polyp, cervicitis, vaginal infection, trauma and hormonal breakthrough bleeding can cause postcoital or intermenstrual bleeding. A visibly benign explanation does not excuse persistent symptoms, unexplained contact bleeding or a suspicious cervix. High-grade squamous intraepithelial lesion and adenocarcinoma in situ are precursors, not invasive cancer, yet need a defined colposcopy pathway because untreated high-grade disease can progress and occult invasion must be excluded.
Endometrial cancer or hyperplasia becomes particularly important with postmenopausal bleeding, chronic anovulation or a uterine source. Vaginal, vulval, ovarian and gestational malignancies can present with bleeding, discharge or a pelvic mass. Fibroids, adenomyosis, endometrial polyps, pregnancy loss and ectopic pregnancy belong in the differential according to reproductive context. Haematuria and rectal bleeding may be misidentified as vaginal. Pelvic inflammatory disease is more likely with pain, fever, discharge and tenderness, but infection and cancer can coexist.
Advanced cervical cancer can resemble urinary, gastrointestinal or musculoskeletal disease through hydronephrosis, constipation, fistula, sciatica or bone pain. Tuberculosis and chronic infection may mimic malignant inflammation in India, but empiric treatment without biopsy can delay cancer care. Histology also matters: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, neuroendocrine carcinoma and metastasis to the cervix have different implications. Lymphoma, sarcoma and benign cervical masses are uncommon but possible. Diagnostic discipline means confirming tissue, reconciling pathology with the clinical lesion, and reopening the differential when results are discordant.
Management
Management begins with a verified biopsy, stage and multidisciplinary plan. Very early, carefully selected disease may be treated with conisation or fertility-sparing trachelectomy after assessment of margins, depth, lymphovascular invasion, tumour size and nodal risk. Other early cancers may require radical hysterectomy with nodal assessment or definitive radiotherapy-based treatment. Surgical approach, extent of parametrial resection and node strategy must follow current specialist standards; evidence that changed minimally invasive radical hysterectomy practice illustrates why old operative summaries should not be applied uncritically.
For many locally advanced cancers, concurrent platinum-based chemoradiation with external-beam radiotherapy and brachytherapy is a curative standard. Brachytherapy is an integral component, not an optional cosmetic addition, when definitive radiation is selected. Treatment time, renal function, marrow reserve, nutrition, anaemia, infection and ability to attend repeated sessions affect delivery. Advanced, persistent or recurrent disease may be considered for surgery in exceptional central recurrences, systemic therapy guided by prior treatment and biomarkers, radiotherapy for symptom control, clinical trials, or integrated palliative care. The NCI PDQ lists broad options but is a United States evidence summary, not an Indian formulary or reimbursement rule.
Across stages, address pain, bleeding, anaemia, urinary obstruction, thrombosis, nutrition, sexual health, fertility, premature menopause, lymphoedema and psychological distress. Discuss ovarian or fertility preservation before treatment when oncologically safe and time permits; do not promise preservation. Follow-up should assess symptoms and treatment effects rather than rely on a scan schedule copied from another jurisdiction. In India, the chosen pathway must be executable: confirm pathology review, radiotherapy and brachytherapy capacity, transport, accommodation, financing, contact routes and continuity between district and tertiary services.
Prescribing Information
Anti-cancer prescribing must remain within a verified gynaecological-oncology protocol. Before systemic treatment, confirm histology, FIGO stage, treatment intent, previous therapy, performance status, pregnancy status or potential, height and weight when relevant, allergies, comorbidities, concurrent medicines, renal and hepatic function, blood count, infection risk and consent. Document the protocol source, cycle, route, dose calculations, hydration, antiemesis, laboratory thresholds, interactions and criteria to hold, reduce or stop treatment. The drug classes named in this guide are not a prescription.
Cisplatin is commonly used as a radiosensitiser in definitive chemoradiation, but dosing and eligibility depend on renal function, hearing, neuropathy, hydration, electrolyte status and local protocol. Other cytotoxic, anti-angiogenic, targeted or immune therapies may be used in advanced or recurrent disease after specialist assessment and biomarker testing. These agents can cause myelosuppression, infection, bleeding, thrombosis, hypertension, renal injury, neuropathy, fistula or perforation, and immune-mediated toxicities affecting multiple organs. Previous pelvic radiotherapy and tumour invasion can materially alter risk.
Fever or acute deterioration during systemic therapy requires immediate use of the treating service's neutropenic-sepsis pathway. Heavy bleeding, chest pain, dyspnoea, new confusion, uncontrolled vomiting, severe diarrhoea, reduced urine output, unilateral leg swelling or an infusion reaction needs urgent assessment. Provide a 24-hour oncology contact and written toxicity instructions. Analgesics, antiemetics, bowel regimens, thrombosis management and antibiotics require individual verification. Avoid unreviewed herbal or traditional products because interactions, bleeding and organ toxicity may occur. HPV vaccination prevents future infection-related disease; it is not a treatment for invasive cancer.
When to Refer
Arrange an urgent gynaecology or gynaecological-oncology pathway for a suspicious cervical lesion, unexplained postcoital or postmenopausal bleeding, persistent blood-stained or offensive discharge, abnormal examination, or symptoms that persist despite an apparently benign initial explanation. A positive screening test needs the programme-defined triage or colposcopy pathway; it should not be relabelled as cancer. Conversely, symptoms or a visible lesion require diagnostic assessment even after a recent negative screen. The referral should include the exact symptoms and duration, pregnancy status, observations, examination findings, haemoglobin and renal results if available, prior screening and treatment records, HIV or immunosuppression, comorbidity, medicines and contact needs.
After biopsy confirmation, refer to a centre able to provide gynaecological oncology, pathology review, radiology, radiation oncology including brachytherapy, medical oncology and supportive care as stage requires. Early referral before performing non-oncological excision can preserve staging and treatment options. Fertility wishes should be stated explicitly but never delay control of bleeding, sepsis or obstruction. Patients with suspected hydronephrosis, severe anaemia, progressive renal impairment, leg swelling, fistula, uncontrolled pain or major nutritional decline need expedited coordination.
Emergency transfer is appropriate for haemodynamic instability, ongoing major bleeding, sepsis, acute kidney injury with obstruction, pulmonary embolism, bowel obstruction, spinal cord or cauda equina features, or life-threatening treatment toxicity. A referral is incomplete if the receiving facility cannot be reached. In Indian settings with variable capacity, confirm the destination, appointment, required pathology blocks and imaging, financial-navigation options, transport and whom the patient should contact if symptoms worsen while waiting.
Red Flags
Major vaginal haemorrhage can present with flooding, clots, tachycardia, hypotension, syncope, chest discomfort or dyspnoea. Resuscitate, establish venous access, obtain blood count and cross-match as indicated, activate the local haemorrhage pathway and involve gynaecology, interventional radiology or radiation oncology urgently. Do not repeatedly manipulate a friable tumour in an unstable patient. Fever, rigors, offensive discharge, pelvic pain, hypotension or confusion suggests infection or necrosis and requires sepsis assessment alongside tumour control.
Flank pain, oliguria, rising creatinine, vomiting or bilateral hydronephrosis can indicate ureteric obstruction. New unilateral leg swelling, pleuritic pain, haemoptysis or acute breathlessness raises concern for venous thromboembolism. Progressive back pain, limb weakness, saddle sensory change or bladder and bowel dysfunction requires emergency assessment for spinal or cauda equina compression. Persistent vomiting, abdominal distension and obstipation may represent bowel obstruction. Vesicovaginal or rectovaginal fistula can cause continuous leakage, infection, skin injury and profound distress; it warrants specialist and supportive care, not blame.
During treatment, fever with possible neutropenia, severe dehydration, inability to pass urine, heavy bleeding, acute neurological symptoms, severe chest or abdominal pain and anaphylaxis are emergencies. After radiotherapy, severe diarrhoea, bleeding, urinary symptoms or later fistula require evaluation; attribution to expected radiation effects without examination can miss recurrence or another disease. Any possibility of pregnancy changes radiation and drug decisions. Psychosocial red flags include suicidal thoughts, violence, abandonment, inability to obtain food or reach treatment, and catastrophic financial risk. Safe cancer care recognises these threats early and activates practical support.
Indian Clinical Context
India's Operational Framework for Management of Common Cancers describes a public-service pathway for breast, cervical and oral cancer, including screening, referral, diagnosis and treatment links from community and primary care to district and tertiary facilities. Its cervical algorithm uses VIA within that programme and directs positive or suspicious findings to trained clinicians. The document is historically important but predates the WHO 2021 shift toward HPV DNA testing as the preferred primary screening approach where programmes can support it. It must not be represented as proof that one screening modality, interval or triage pathway is uniformly current across every Indian state.
A clinician should identify the actual state or institutional programme: eligible age group, test used, rescreen interval, HIV pathway, triage after HPV positivity or VIA, eligibility for ablative treatment, referral thresholds and tracking system. Screen-and-treat recommendations concern eligible precancer after exclusion of suspected invasion. A lesion suspicious for cancer requires biopsy and oncology referral, not blind ablation. Quality depends on sample integrity, trained examination, infection prevention, pathology or triage capacity, treatment completion and active recall after abnormal results.
Cancer treatment capacity varies. MRI, PET-CT, experienced radical surgery, image-guided brachytherapy, biomarker testing and some systemic medicines may not be locally available. Teams should avoid ordering inaccessible tests that do not change a feasible plan, while also avoiding undertreatment solely because a patient first presents in a lower-resource setting. Teleconsultation, pathology transfer and government or charitable schemes may help, but availability must be verified. WHO and NCI sources inform principles; final treatment must follow the current Indian specialist protocol, medicines regulation, facility capability and the patient's preferences and constraints.
NMC Competency Mapping
The NMC undergraduate curriculum maps cervical neoplasia to Obstetrics and Gynaecology competencies OG33.1 through OG33.4. OG33.1 requires learners to classify and discuss aetiology, pathology, clinical features, differential diagnosis, investigations and staging of cervical cancer. OG33.2 addresses principles of management of benign, premalignant and malignant cervical lesions, including surgery and radiotherapy. OG33.3 requires description and demonstration of cervical-cancer screening in a simulated environment, while OG33.4 covers prevention methods including VIA, VILI, cytology and colposcopy.
At Know and Know How levels, a learner should explain HPV persistence and the transformation zone, distinguish screening from diagnosis, recognise warning symptoms, construct a differential for postcoital or postmenopausal bleeding, describe biopsy and staging, and outline stage-directed multidisciplinary treatment. They should understand why invasive disease is not treated with a screening algorithm and why brachytherapy matters in definitive radiation. Prevention answers should include vaccination, screening quality and treatment of high-grade precancer rather than listing tests without a follow-up system.
At Show How level, learners may counsel about screening, obtain informed consent, prepare equipment, demonstrate a programme-approved screening procedure on a simulator and explain results and referral. A simulated competency does not authorise unsupervised screening, colposcopy, biopsy or treatment. Teaching should integrate pathology, microbiology, community medicine, radiology, surgery, oncology, communication and palliative care. The institution's current logbook governs assessment. This guide uses the competency identifiers as educational anchors and does not claim that its foreign evidence sources define NMC clinical policy.
Key Exam Pearls for NEET PG
Persistent oncogenic HPV infection drives almost all cervical cancers. The transformation zone is the key site for squamous precancer, and squamous-cell carcinoma is the commonest invasive histology. HPV 16 and 18 are high-yield oncogenic types, but vaccination and screening policies involve more than two types. Screening applies to people without symptoms; postcoital bleeding, postmenopausal bleeding, persistent watery or offensive discharge, contact bleeding or a visible growth requires diagnostic evaluation. Cytology reports cellular abnormality, HPV testing detects viral nucleic acid, VIA reveals acetowhite change and colposcopy directs assessment; none alone proves stromal invasion.
Cervical intraepithelial neoplasia is a precursor spectrum, whereas invasive cancer requires histological breach of the basement membrane. Biopsy establishes diagnosis. FIGO staging is fundamentally clinical with imaging and pathology incorporated where available; stage and nodal status direct treatment. Very early selected disease may permit conisation or fertility-sparing surgery. Early operable disease may be treated surgically, while locally advanced disease is classically managed with concurrent chemoradiation including brachytherapy. Do not omit brachytherapy in an exam answer about definitive radiation.
Hydronephrosis or a non-functioning kidney from tumour has staging and urgency implications. Pelvic-wall involvement, lower vaginal extension, bladder or rectal mucosal invasion, and distant metastasis represent progressively advanced disease concepts. Major bleeding, obstructive uropathy, fistula, thromboembolism and sepsis are important complications. Cisplatin radiosensitisation requires renal and toxicity assessment. HPV vaccine is preventive, not therapeutic. A strong answer separates population screening, diagnostic biopsy, staging and treatment, states fertility considerations before therapy, and never reassures a symptomatic patient because a previous screening result was negative.
Frequently Asked Questions
Can a normal recent cervical screening result rule out cancer when symptoms develop?
No. Screening reduces risk but is not a diagnostic guarantee, and false-negative results or interval disease can occur. Postcoital or postmenopausal bleeding, persistent blood-stained discharge or a suspicious cervix needs clinical assessment and usually specialist evaluation regardless of the date of the last screen.
Does a positive high-risk HPV test mean that the person has cervical cancer?
No. It indicates infection with an oncogenic HPV type, and most infections do not become cancer. The result must enter the programme-defined triage pathway. Cancer is diagnosed by evaluating a suspicious lesion and confirming invasive disease histologically, not by HPV testing alone.
Is fertility-preserving treatment possible after a cervical cancer diagnosis?
It may be possible for carefully selected small, early cancers after specialist review of stage, histology, tumour dimensions, margins and nodal risk. Conisation or radical trachelectomy can be considered in defined circumstances, but preservation is not oncologically safe for every tumour and pregnancy outcomes require separate counselling.
Why is brachytherapy important in definitive treatment of locally advanced cervical cancer?
Brachytherapy delivers a concentrated radiation dose to the cervix and adjacent tumour while limiting exposure of surrounding organs. When definitive radiotherapy is chosen, external-beam treatment without the planned brachytherapy component can compromise local treatment. Technique, dose and timing require a specialist radiation-oncology service.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic